Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics

Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director
for Orthopaedics

PARSIPPANY, N.J., Oct. 29 /PRNewswire/ -- Ferring Pharmaceuticals Inc.
announces the appointment of Harry F. Kovelman, MD as Associate Medical
Director for Orthopaedics. Dr. Kovelman will be responsible for medical
affairs for EUFLEXXA®( ) (1% sodium hyaluronate), a treatment for knee pain
due to osteoarthritis, as well as Ferring's expanding line of orthopaedic
products.

"Dr. Kovelman is exceptionally well qualified to fill this role," said Edward
Trott, MD, Vice President, Medical Affairs. "His experience and knowledge in
the field of orthopaedic medicine will provide valuable insight as we continue
to build upon our success with EUFLEXXA®."

Dr. Kovelman joins Ferring with a broad range of experience in medical
affairs, business development, sales and marketing in the medical and
orthopaedic device industries. Prior to joining Ferring, Dr. Kovelman was
Director of Medical Affairs at Otto Bock HealthCare, which provides equipment
for restorative health. He has also served as Chief Executive Officer of
Archimedes Medical Technology, a consulting services company for the medical
device industry; Executive Director, Orthopaedic Institute of St. Joseph
Medical Center in Maryland; and Medical Affairs Director and Vice President of
Sales and Marketing at Dynasplint Systems, Inc., manufacturer of medical
devices for range-of-motion loss.

Dr. Kovelman received his Doctor of Medicine degree from the Universidad Del
Noreste in Mexico, and Bachelor of Science degree in psychology from the
University of Maryland.

About EUFLEXXA®( )
EUFLEXXA®( ) (1% sodium hyaluronate) is the first non-avian derived*
hyaluronic acid (HA) approved in the U.S. for treatment of knee pain due to
osteoarthritis (OA). EUFLEXXA® is indicated for patients who have failed to
get adequate pain relief either from simple pain medications, such as
acetaminophen, or from exercise and/or physical therapy. The process used to
manufacture EUFLEXXA® results in highly-purified HA with properties similar to
the HA in healthy human synovial fluid.(1-4) EUFLEXXA® received approval from
the U.S. Food and Drug Administration (FDA) on December 3, 2004 and became
available to the public on November 8, 2005. For more information, visit
www.EUFLEXXA.com.

EUFLEXXA® should not be used in people who have had any previous allergic
reaction to hyaluronate preparations or who have knee joint infections or skin
diseases in the area of the injection site. Common adverse events reported
were arthralgia (joint pain) and back pain. Temporary knee pain and swelling
may occur after injection. Strict aseptic technique must be followed to avoid
joint infection.

About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a
privately owned, international pharmaceutical company. Ferring
Pharmaceuticals offers a line of infertility, urology, and orthopaedic
products in the U.S. market. They include: BRAVELLE® (urofollitropin for
injection, purified), MENOPUR®( )and REPRONEX® (menotropins for injection,
USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN®
(progesterone) Vaginal Insert, 100 mg, FIRMAGON®( ) (degarelix for injection),
PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid,
hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and
commercialization of compounds in general and pediatric endocrinology,
urology, orthopaedics, gastroenterology, obstetrics/gynecology, and
infertility. For more information, call 1-888-FERRING (1-888-337-7464) or
visit www.FerringUSA.com.

*Derived through bacterial fermentation

(1) Data on File, Ferring Pharmaceuticals.
(2) ( )Kirchner M, Marshall D. A double-blind randomized controlled trial
comparing alternate forms of high molecular weight hyaluronan for the
treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;
14:154-162.
(3) ( )Schiavinato A, Finesso M, Cortivo R, & Abatangelo G (2002). Comparison
of the effects of intra-articular injections of Hyaluronan and its chemically
cross-linked derivative (Hylan G-F20) in normal rabbit knee joints. Clin Exp
Rheumatol 20, 445-454.
(4) Goomer RS, Leslie K, Maris T, & Amiel D (2005). Native hyaluronan produces
less hypersensitivity than cross-linked hyaluronan. Clin Orthop Relat Res
239-245.

SOURCE Ferring Pharmaceuticals Inc.

Tara Fisher, Kovak-Likly Communications, +1-203-762-8833, tfisher@klcpr.com